Risk factor
Very vulnerable to price shocks
Profitability factor
Very strong margins and returns
About
CellaVision AB (publ), a Swedish enterprise established in 1994 and based in Lund, specializes in crafting and distributing advanced digital systems for analyzing blood and other bodily fluids within the healthcare industry. The company serves a global market, with operations extending across Sweden, the wider European continent, the Middle East, Africa, the Americas, and the Asia Pacific region. Their core product line includes automated digital imaging devices such as the CellaVision DM1200 and DM9600, engineered to automatically capture detailed digital images of cells from blood smears and fluid preparations. Additionally, they offer the CellaVision DC-1 analyzer. Beyond hardware, CellaVision provides a suite of specialized software applications. The CellaVision Peripheral Blood Application streamlines and standardizes the morphological assessment of peripheral blood smears, while the CellaVision Advanced RBC Application facilitates a thorough examination of red blood cell morphology. For other body fluids, the CellaVision Body Fluid Application automates and standardizes their morphological evaluation. To enhance operational flexibility, the CellaVision Remote Review Software allows for the review of digital smears without geographical restrictions. Furthermore, the company delivers tools designed for laboratory management and educational purposes. The CellaVision Server Software integrates workflows across single or multiple testing facilities into a cohesive system. The CellaVision Dashboard provides an instant, visual summary of analyzer and reviewer performance data. The cloud-based CellaVision Proficiency Software assists laboratory managers in evaluating, tracking, and developing staff competency in cell morphology. For training and reference, the CellaVision CellAtlas features concise educational modules alongside a comprehensive cell image library. CellaVision also caters to the animal health sector with CellaVision VET, offering digital microscopy solutions for veterinary hematology. These innovative solutions are primarily supplied to hospitals and commercial laboratories worldwide.
Company Valuation
Based on key historical and expected multiples, the stock is overvalued relative to its peers. In particular, the stock is reasonably priced on P/E, of fair value on EV/E
Target Price
The average target price of CEVI.ST is 186 and suggests 15.3% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to in